Investor Affinity Asset Advisors, LLC
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Affinity Asset Advisors, LLC . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Date Form Target Prev
Shares
Current
Shares
Change
(Percent)
Ownership
(Percent)
Change
(Percent)
2025-08-26 13G IBIO / iBio, Inc. 4,280,000
2025-06-04 13G LXEO / Lexeo Therapeutics, Inc. 4,252,005
2025-05-30 13G VTYX / Ventyx Biosciences, Inc. 4,057,105
2025-05-30 13G/A INZY / Inozyme Pharma, Inc. 3,972,318 1,867,710
2025-04-10 13G KPTI / Karyopharm Therapeutics Inc. 664,224
2024-12-31 13G AVTX / Avalo Therapeutics, Inc. 550,765
2024-12-09 13G INZY / Inozyme Pharma, Inc. 3,972,318
2024-11-13 13G/A NXTC / NextCure, Inc. 1,672,839 2,302,598
2024-08-14 13G/A CLYM / Climb Bio, Inc. 1,670,000 1,813,193
2024-06-27 13G NXTC / NextCure, Inc. 1,672,839
2024-05-07 13G CLYM / Climb Bio, Inc. 1,670,000
2024-02-13 13G/A VINC / Vincerx Pharma, Inc. 1,492,771 0
2024-02-13 13G/A SYRE / Spyre Therapeutics, Inc. 653,409
2024-02-13 13G/A CNTX / Context Therapeutics Inc. 883,654 328,817
2023-07-03 13G AGLE / Aeglea BioTherapeutics Inc 7,477,000
2023-02-13 13G/A VINC / Vincerx Pharma, Inc. 1,135,365 1,492,771
2022-05-09 13G CNTX / Context Therapeutics Inc. 883,654
2022-02-11 13G/A VINC / Vincerx Pharma, Inc. 1,076,220 1,135,365
2021-11-22 13G VINC / Vincerx Pharma, Inc. 1,076,220